Skip to content

G1 Therapeutics, Inc.

Delisted

CIK 1560241fmd_1HCQZCS00X5F0VA1AQHDXZREZ7Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2015 to Jun 30, 2024, 35 periods

Latest annual · FY2023

Millions
Total revenues
83
Operating income
(40)
Net income
(48)
Free cash flow
(38)

Latest quarter · Q2 FY2024

Millions
Total revenues
17
Operating income
(4)
Net income
(5)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2020 to FY2023
+22.1%
Revenue, 5 yearsFY2018 to FY2023
n/m
Net income, 5 yearsFY2018 to FY2023
n/m

G1 Therapeutics, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2023FY2022ChangeSource
Revenue$82.5 million$51.3 million+60.8%10-K 2024-02-28 · proof
Operating income-$39.5 million-$136.2 million10-K 2024-02-28 · proof
Net income-$48 million-$147.6 million10-K 2024-02-28 · proof
Cash from operating activities-$38.3 million-$128.6 million10-K 2024-02-28 · proof
Free cash flow-$38.3 million-$129.1 million10-K 2024-02-28 · proof
Total assets$121.5 million$188 million-35.3%10-K 2024-02-28 · proof
Total liabilities$86.2 million$119.2 million-27.7%10-K 2024-02-28 · proof
Cash and cash equivalents$32.2 million$94.6 million-65.9%10-K 2024-02-28 · proof
Total debt$51.6 million10-Q 2024-05-01 · proof
What was G1 Therapeutics, Inc.'s revenue in fiscal 2023?
G1 Therapeutics, Inc. reported revenue of $82.5 million for fiscal 2023 (the year ended Dec 31, 2023), against $51.3 million the year before (+60.8%). Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
What was G1 Therapeutics, Inc.'s operating income in fiscal 2023?
G1 Therapeutics, Inc. reported operating income of -$39.5 million for fiscal 2023 (the year ended Dec 31, 2023), against -$136.2 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
What was G1 Therapeutics, Inc.'s net income in fiscal 2023?
G1 Therapeutics, Inc. reported net income of -$48 million for fiscal 2023 (the year ended Dec 31, 2023), against -$147.6 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
What was G1 Therapeutics, Inc.'s cash from operating activities in fiscal 2023?
G1 Therapeutics, Inc. reported cash from operating activities of -$38.3 million for fiscal 2023 (the year ended Dec 31, 2023), against -$128.6 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
What was G1 Therapeutics, Inc.'s free cash flow in fiscal 2023?
G1 Therapeutics, Inc. reported free cash flow of -$38.3 million for fiscal 2023 (the year ended Dec 31, 2023), against -$129.1 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
What are G1 Therapeutics, Inc.'s total assets?
As of Dec 31, 2023, G1 Therapeutics, Inc. reported total assets of $121.5 million, against $188 million a year earlier (-35.3%). Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
What are G1 Therapeutics, Inc.'s total liabilities?
As of Dec 31, 2023, G1 Therapeutics, Inc. reported total liabilities of $86.2 million, against $119.2 million a year earlier (-27.7%). Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
What are G1 Therapeutics, Inc.'s cash and cash equivalents?
As of Dec 31, 2023, G1 Therapeutics, Inc. reported cash and cash equivalents of $32.2 million, against $94.6 million a year earlier (-65.9%). Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
What is G1 Therapeutics, Inc.'s total debt?
As of Dec 31, 2023, G1 Therapeutics, Inc. reported total debt of $51.6 million. Source: the 10-Q filed with the SEC on May 1, 2024. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1560241&period_type=annual&limit=5"

Information only, not investment advice.